Adicet Bio, Inc. (0HX7.L)

2.1750 -0.1650 (-7.05%) At close: 02:42PM BST

Adicet Bio, Inc.

131 Dartmouth Street
3rd Floor
Boston, MA 02116
United States
650 503 9095
https://www.adicetbio.com

Sector(s): 
Industry: 
Full-time employees: 143

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Chen Schor BA, CPA, M.B.A.	CEO, President & Director	899.58k	N/A	1972
Dr. Aya Jakobovits Ph.D.	Founder & Independent Director	40k	N/A	1956
Dr. Blake Aftab Ph.D.	Senior VP & Chief Scientific Officer	675.04k	N/A	1981
Dr. Francesco Galimi M.D., Ph.D.	Chief Medical Officer & Senior VP	680.37k	N/A	1968
Mr. Brian Nicholas Harvey	Chief Financial Officer	596.79k	N/A	1961
Dr. Donald Healey Ph.D.	Chief Technology Officer	N/A	N/A	1962
Ms. Amy Locke	Chief Human Resource Officer	N/A	N/A	N/A
Dr. Nancy L. Boman M.D., Ph.D.	Senior VP & Chief Regulatory Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Corporate governance

Adicet Bio, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.